Atlas Trials

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Clinical trial NCT07001618 · RECRUITING

Trial details

NCT number
NCT07001618
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC (Advanced Non-small Cell Lung Cancer)
Start date
2025-11-17
Primary completion
2030-09-01
Enrollment
162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.